Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human milk oligosaccharides + bifidobacterium infantis
- Development stage
- Unknown
- Lead developer
- International Flavors & Fragrances
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This product is a **synbiotic combination** consisting of **human milk oligosaccharides (HMOs)**—complex carbohydrates found in human breast milk—and **Bifidobacterium longum subsp. infantis** (commonly known as *Bifidobacterium infantis*), a probiotic bacterium that naturally colonizes the infant gut. HMOs serve as prebiotics that specifically promote the growth and metabolic activity of B. infantis, which can effectively digest a broad range of HMOs. This synergistic relationship results in increased production of beneficial short-chain fatty acids (especially acetate), supports healthy gut colonization, enhances innate immune development, and may favorably modulate inflammatory responses. Clinical evidence suggests this combination may reduce the risk of necrotizing enterocolitis in preterm infants, improve gut microbiota balance in infants, and possibly alleviate symptoms of functional gastrointestinal disorders like irritable bowel syndrome in children[2][3][7].
- Other names
- human milk oligosaccharides and Bifidobacterium infantisHMO + B. infantishuman milk oligosaccharides plus Bifidobacterium infantis
02
Targets
Bifidobacterium longum subsp. infantis carbohydrate transporters and glycosyl hydrolases
Beyond the preview
Go deeper on human milk oligosaccharides + bifidobacterium infantis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human milk oligosaccharides + bifidobacterium infantis.